We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

180 hedge funds and large institutions have $783M invested in Meridian Bioscience Inc in 2021 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 47 increasing their positions, 74 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

6% less call options, than puts

Call options by funds: $7M | Put options by funds: $7.48M

5% less funds holding

Funds holding: 189180 (-9)

17% less capital invested

Capital invested by funds: $941M → $783M (-$157M)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

36% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 74

Holders
180
Holders Change
-9
Holders Change %
-4.76%
% of All Funds
3.15%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
22
Increased
47
Reduced
74
Closed
28
Calls
$7M
Puts
$7.48M
Net Calls
-$475K
Net Calls Change
+$3.25M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$140M -$2.53M -127,024 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$96.3M -$1.42M -71,162 -1%
EARNEST Partners
3
EARNEST Partners
Georgia
$75.1M +$355K +17,812 +0.5%
RA
4
Royce & Associates
New York
$41M +$1.8M +90,084 +4%
DM
5
Deerfield Management
New York
$39.7M +$12.7M +638,809 +45%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$35.7M +$706K +35,423 +2%
State Street
7
State Street
Massachusetts
$35.3M +$751K +37,659 +2%
Renaissance Technologies
8
Renaissance Technologies
New York
$34.8M -$1.23M -61,800 -3%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$15.9M -$2.04M -102,580 -11%
SFM
10
Systematic Financial Management
New Jersey
$15.2M +$45.1K +2,261 +0.3%
New York State Common Retirement Fund
11
New York State Common Retirement Fund
New York
$14.7M -$157K -7,875 -1%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$12.8M +$4.88M +244,979 +58%
Charles Schwab
13
Charles Schwab
California
$11.2M +$13.8K +690 +0.1%
N
14
Nuveen
North Carolina
$10.9M -$2.23M -112,002 -16%
Northern Trust
15
Northern Trust
Illinois
$10.9M -$358K -17,940 -3%
VLKIM
16
Van Lanschot Kempen Investment Management
Netherlands
$10.6M +$2.73M +136,880 +33%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$8.92M -$218K -10,945 -2%
FWIA
18
Fort Washington Investment Advisors
Ohio
$8.52M
Wells Fargo
19
Wells Fargo
California
$8.39M -$352K -17,676 -4%
LSV Asset Management
20
LSV Asset Management
Illinois
$7.43M -$267K -13,400 -3%
Principal Financial Group
21
Principal Financial Group
Iowa
$6.84M -$94.3K -4,733 -1%
Invesco
22
Invesco
Georgia
$6.3M -$895K -44,915 -12%
AI
23
Acuitas Investments
Washington
$6.12M +$678K +34,034 +12%
Allianz Asset Management
24
Allianz Asset Management
Germany
$5.86M +$116K +5,811 +2%
Millennium Management
25
Millennium Management
New York
$5.22M -$2.59M -129,745 -32%

VIVO Hedge Fund Activity: Q3 2021 in Review

180 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q3 2021, worth a combined $783M — down 17% from $941M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of VIVO and 22 opened new positions — a net loss of 6 holders — while 74 trimmed existing stakes and 47 added.

The largest buyer was Deerfield Management, adding an estimated $12.7M. The largest seller was Fuller & Thaler Asset Management, cutting an estimated $29.8M.

  • 180 institutional investors held Meridian Bioscience Inc (VIVO) as of Q3 2021, down from 189 in Q2 2021.
  • Funds reported $783M of Meridian Bioscience Inc stock for Q3 2021, down 17% quarter-over-quarter.
  • 22 funds opened new Meridian Bioscience Inc positions in Q3 2021 and 28 closed out, a net change of -6 holders.
  • The largest Meridian Bioscience Inc buyer in Q3 2021 was Deerfield Management, an estimated $12.7M added.
  • The largest Meridian Bioscience Inc seller in Q3 2021 was Fuller & Thaler Asset Management, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2021.